Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesPrediction of Diabetic Nephropathy Using Urine Proteomic Profiling 10 Years Prior to Development of Nephropathy
Diabetes Care, 03/05/07
Hasan H. Otu, PHD., et al. – Is proteomic profiling valuable in identifying progression of diabetic nephropathy?
>Summary: In a nested case-control study of Pima Indians with type 2 diabetes, baseline and 10-year urine samples were examined. Thirty one case subjects developed diabetic nephropathy over 10 years. The same number of control subjects were matched to case subjects according to diabetes duration, age, sex, and BMI but remained normoalbuminuric over the same 10 years. The study examined whether proteomic technologies could identify novel urine proteins associated with subsequent development of diabetic nephropathy.
Outcomes: Urine proteomic profiling identifies normoalbuminuric subjects with type 2 diabetes who subsequently develop diabetic nephropathy. Further studies are needed to characterize the specific proteins involved in this early prediction
| Previous Article | Next Article |
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09
A randomized trial of therapies for type 2 diabetes and coronary artery disease
New England Journal of Medicine, 06/10/09
Sponsor
Article Search
Sponsor